human
coronavirus
cov
increasingli
recogn
import
respiratori
pathogen
associ
broad
rang
clinic
diseas
sought
increas
insight
clinic
relev
cov
infect
monitor
antigen
concentr
six
confirm
covposit
patient
use
newli
develop
assay
rapid
detect
cov
infect
antigen
posit
last
day
secondari
infect
day
primari
infect
cov
infect
clinic
divers
common
diagnos
clinic
symptom
alon
coronavirus
cov
larg
envelop
singlestrand
positivesens
rna
virus
belong
coronavirida
famili
although
first
two
human
alreadi
discov
special
attent
given
infect
primarili
selflimit
associ
symptom
mild
common
cold
sinc
sever
new
cov
type
emerg
world
health
organ
issu
global
alert
deadli
new
infecti
diseas
sever
acut
respiratori
syndrom
turn
caus
cov
late
novel
cov
isol
two
children
respiratori
symptom
netherland
follow
discoveri
patient
pneumonia
middl
east
respiratori
syndrom
cov
identifi
acknowledg
one
danger
respiratori
virus
human
result
cov
increasingli
recogn
import
pathogen
associ
broad
rang
clinic
diseas
previou
studi
report
preval
cov
mani
countri
viru
isol
cell
cultur
recent
molecular
techniqu
specif
pcr
method
choic
diagnos
cov
infect
sever
disadvantag
commerci
pcrbase
method
often
rel
expens
requir
technic
expertis
presenc
viral
rna
dna
alway
reflect
acut
diseas
moreov
use
pcr
cov
frequent
codetect
respiratori
virus
contribut
posit
cov
pcr
result
diseas
sever
alway
clear
despit
high
morbid
mortal
associ
infect
caus
specif
cov
frequent
detect
cov
patient
respiratori
infect
rapid
method
avail
detect
clinic
relev
cov
human
aim
studi
increas
insight
clinic
relev
cov
infect
monitor
antigen
concentr
confirm
cov
patient
use
newli
develop
assay
rapid
detect
infect
assay
detect
speciesspecif
nucleoprotein
antigen
introduc
maripoc
respi
test
maripoc
arcdia
int
ltd
turku
finland
autom
multianalyt
antigen
detect
test
system
enabl
rapid
detect
acut
infect
besid
recent
ad
maripoc
respi
test
abl
detect
nine
respiratori
virus
influenza
b
virus
respiratori
syncyti
viru
adenoviru
human
metapneumoviru
parainfluenzaviru
type
human
bocaviru
streptococcu
pneumonia
one
nasopharyng
sampl
point
care
new
cov
antigen
test
analyt
sensit
ngml
recombin
antigen
test
crossreact
neither
common
respiratori
pathogen
microbiota
therefor
unlik
crossreact
either
middl
east
respiratori
syndrom
cov
sever
acut
respiratori
syndrom
cov
accord
manufactur
specif
clinic
specif
test
n
compar
pcr
studi
use
semiquantit
properti
maripoc
analysi
obtain
cov
antigen
level
extrapol
standard
concentr
curv
verif
result
sampl
sent
two
laboratori
laboratori
clinic
virolog
academ
medic
center
amc
netherland
nation
institut
health
welfar
thl
finland
pcr
test
multiplex
rtpcr
covspeciesspecif
rtpcr
respect
prospect
follow
six
otherwis
healthi
immunocompet
finnish
volunt
develop
respiratori
ill
symptom
test
posit
maripoc
assay
decemb
decemb
inform
consent
obtain
patient
parent
enrol
verif
symptom
nasopharyng
swab
collect
daili
onset
diseas
disappear
symptom
patient
neg
ten
pathogen
cover
maripoc
respi
test
maripoc
analysi
sampl
frozen
aliquot
sent
amc
thl
confirm
result
antigen
measur
result
almost
daili
collect
sampl
shown
fig
antigen
secret
correl
rel
well
symptom
sever
clinic
characterist
covposit
patient
provid
tabl
sampl
measur
cov
antigen
level
maripoc
also
posit
pcr
frequent
detect
potenti
sever
complic
associ
cov
infect
new
diagnost
method
rapidli
identifi
infect
need
newli
develop
cov
antigen
assay
success
monitor
six
covposit
patient
show
cov
infect
clinic
divers
also
shown
earlier
studi
diagnos
basi
clinic
symptom
result
suggest
assay
could
potenti
identifi
patient
cov
real
caus
infect
measur
viru
antigen
level
need
detect
achiev
acut
phase
infect
also
case
influenza
howev
larger
studi
patient
need
confirm
find
determin
full
diagnost
accuraci
new
assay
young
age
sever
ill
episod
long
viru
posit
time
suggest
patient
probabl
primari
infect
basi
patient
age
data
seropreval
studi
case
like
secondari
infect
interestingli
patient
diagnos
posit
month
infect
describ
data
shown
confirm
widespread
preval
possibl
reinfect
appar
lack
protect
immun
subtyp
cov
monitor
antigen
concentr
suggest
viru
load
peak
around
third
fourth
day
symptom
onset
confirm
find
experiment
studi
adney
et
al
sampl
therefor
done
within
first
day
symptom
onset
order
ensur
maximum
sensit
antigen
detect
test
patient
like
primari
infect
show
antigen
posit
day
week
longer
posit
time
adult
usual
observ
virus
prompt
test
diagnosi
maxim
potenti
affect
treatment
decis
prescrib
virusspecif
drug
predict
clinic
cours
withhold
prescript
antibiot
new
rapid
test
might
therefor
valuabl
contribut
patient
care
